Abbott Laboratories Q4 FY2025 earnings call

• 2025 Highlights: Achieved innovation milestones (regulatory approvals, new indications, trial enrollments, filings), disciplined execution with top-tier margin expansion and double-digit earnings growth despite challenges, and announced acquisition of Exact Sciences to enter the cancer diagnostics market.
• Fourth Quarter Details: Nutrition facing volume growth challenges, with initiatives to reignite volume growth through price and promotion initiatives and increased innovation focus. Diagnostics saw sales growth, EPD continued consistent growth, and medical devices had strong performance across segments.
• Innovation and Strategy: Focus on innovation as the foundation of success, investment in high-growth and foundational segments, and strategic moves like the Exact Sciences acquisition to shape future growth.

Nutrition: Sales declined in the quarter. The US pediatric business faced market share loss partly due to a WIC contract loss, and the need to reignite volume growth. Higher manufacturing costs led to price increases constraining volume growth, but initiatives to reignite volume growth were started in Q4. Diagnostics: Sales increased 3.5% due to anticipated year-over-year decline in COVID testing sales. Core Lab Diagnostics grew 3.5% achieving third consecutive quarter of accelerating growth, and point-of-care diagnostics grew 7%. EPD: Sales increased 7% in the quarter with well-balanced growth across markets and therapeutic areas, marking fifth consecutive year of sales growth exceeding 7%. Medical Devices: Sales grew 10.5%. Diabetes care CGM sales grew 12% in Q4 and 17% for the year. Electrophysiology sales grew double digits in US and internationally. Structural heart growth was driven by double-digit growth in Navitor, Triclip, and MitraClip. Heart failure growth was 12% driven by ventricular assist devices and CardioMEMS. Rhythm management growth was 12% led by Aveir. Vascular growth was 6.5% led by vessel closure products and ESPRIT. Neuromodulation growth was 5.5% led by strong international growth.

• Forecast midpoint of 2026 organic sales growth at 7% and midpoint of adjusted EPS growth at 10%.
• Full-year adjusted EPS guidance $5.55-$5.80, organic sales growth range 6.5%-7.5%, expected favorable exchange impact on sales, adjusted tax rate range 15-16%.

• Economic, competitive, governmental, technological factors that may affect operations. Impact of new tariffs and market challenges in China. Price sensitivity affecting nutrition volume growth. Regulatory and clinical trial risks.

Q: Larry Biegelsen asked about guidance change related to nutrition and cadence of growth.

A: Robert Ford explained that nutrition's challenges due to price increases suppressing demand led to guiding lower, with plans to reignite volume growth through price promotion initiatives and new product launches, expecting growth to accelerate in the second half.

Q: David Roman asked about EP pipeline and portfolio context.

A: Robert Ford discussed the strategy for EP products, positive feedback on Volt launch, and confidence in the complete portfolio and team's execution for growth.

Q: Robbie Marcus asked about CGM growth outlook and market position.

A: Robert Ford expressed confidence in CGM growth, citing continued market penetration opportunities in various patient segments and geographies.

Q: Vijay Kumar asked about cap allocation and Exact Sciences deal.

A: Robert Ford discussed capital allocation focus on integration of Exact Sciences, post-close debt ratio, and progress towards closing the deal with shareholder vote on February 20.

Q: Danielle Antalffy asked about nutrition pricing and profitability.

A: Robert Ford stated that pricing initiatives are based on testing and early signs are encouraging, with profitability profile expected to be in line with 2025.

Q: Matt Taylor asked about diagnostics in China and diabetes non-insulin coverage.

A: Robert Ford said diagnostics in China is becoming more stable, and there is support for non-insulin type two coverage with clinical evidence backing it up, expecting language in the first half.

Q: Travis Steed asked about med tech volumes and growth cadence.

A: Robert Ford stated med tech volumes were good in Q4 and growth is expected to improve from first half to second half.

Q: Joanne Wuensch asked about EPD macro landscape and structural heart growth.

A: Robert Ford discussed EPD's resilience and structural heart's strong pipeline with multiple growth catalysts and upcoming launches.

Q: Josh Jennings asked about capital allocation and nutrition recovery.

A: Robert Ford stated focus on med tech and diagnostics for inorganic growth, with nutrition recovery relying on internal initiatives to reignite volume growth